Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.41 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22600490 | 0.94 | ALDH1A1 (0.50) | SIGMAR1ALDH1A1KDM4ENPC1MEN1 | |
| SCHEMBL13032706 | 0.94 | ALDH1A1 (0.50) | SIGMAR1ALDH1A1KDM4ENPC1MEN1 | |
| SCHEMBL26178992 | 0.89 | ALDH1A1 (0.49) | SIGMAR1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL24410021 | 0.88 | MEN1 (0.46) | SIGMAR1ALDH1A1KDM4ENPC1MEN1 | |
| SCHEMBL29300550 | 0.88 | ALDH1A1 (0.47) | SIGMAR1ALDH1A1KDM4ENPC1MEN1 | |
| SCHEMBL18871388 | 0.88 | SIGMAR1 (0.57) | SIGMAR1ALDH1A1KDM4ENPC1USP2 | |
| SCHEMBL5547349 | 0.88 | CASP2 (0.51) | ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL18118429 | 0.88 | CASP2 (0.51) | ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL23824100 | 0.88 | CASP2 (0.51) | ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL254811 | 0.88 | CASP2 (0.51) | ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170072075-A1 | Chelated PSMA Inhibitors | CANCER TARGETED TECHNOLOGY LLC | 2017-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170072075-A1 | Chelated PSMA Inhibitors | FOLH1, KLK3, PSMA1 | SIGMAR1 3316/4885ALDH1A1 1059/4885KDM4E 1788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.